AzTrials
AzTrials

Family MemberNCT02019628

Enhanced Natural Killer Cell Activity and RBAC

A study testing Rice Bran Arabinoxylan Compound (RBAC) in people with Family Member, run by University of Miami at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The present study investigated the effect of RBAC on natural killer cell activity (NKCA) and the production of cytokines and growth factors over 4 weeks among healthy adults. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Family Member
What is being tested?
Rice Bran Arabinoxylan Compound (RBAC)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
Nov 2009to Nov 2011
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Women and men ages 18 years and over.
  • Interest in participating in a novel nutritional supplement program.
  • Willingness to follow recommendations.

Who cannot join

  • Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning.
  • Unable to consent to the study.
  • Women who are pregnant or are attempting conception, especially in the presence of a history of recurrent spontaneous abortion.
  • Other medical complications that might preclude one from participating in the study, i.e., recent heart attack or stroke or chronic kidney disease.
  • Currently taking immunomodulatory medication, i.e. interferon.
  • Currently taking other medications thought to have an impact on immune system functioning, i.e., chemotherapeutic agents.
Show all 10Show fewer
  • Known allergy to rice, rice bran, or related food products.
  • Known allergy to mushrooms or related food products.
  • History of malignancies related to the NK cell line, including: NK cell leukemias and T-cell large granular lymphocyte leukemias, NK-cell lymphoproliferative disease of granular lymphocytes, and NK cell lymphomas, e.g., nasal and nasal-like NK/T-cell lymphomas.
  • Current smoker.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Miami CRB

    Miami, Florida, 33136

Other trials in United States

About this study

Official title: Enhancement of Natural Killer Cell Activity in Healthy Adults by Rice Bran Arabinoxylan Compound, a Novel Oligosaccharide

The present study investigated the effect of RBAC on natural killer cell activity (NKCA) and the production of cytokines and growth factors over 4 weeks among healthy adults.

Read the detailed description

The purpose of this study is to investigate the outcomes of a 60-day trial of Rice Bran Arabinoxylan Compound (RBAC) among adults. Specifically, subjects will participate in a two-group, randomized intervention that is based on a nutritional supplement made from a water soluble extract of rice bran that has been partially hydrolyzed by the action of a natural enzyme complex extracted from Shitake mushroom. One group will take 1 gram/day and the other group will take 3 gram/day to compare differences in outcomes between the two groups. We hypothesize that the 3 gram/day condition will demonstrate faster increases in outcomes compared to the 1 gram/day condition. The primary outcomes for this study will be Natural Killer (NK) cell activity, cytokines, total bilirubin, creatinine, and liver function tests. These outcomes will be compared between those subjects enrolled in the two treatment groups before and after 60 days.

No substantial psychological, medical, or social risks exist to the participants, other than minor discomfort associated with the venipuncture. Although all measures to protect confidentiality will be put in place, the possibility exists that electronic data could be jeopardized. In the remote case that such event occurs, it will be immediately reported to the IRB.

The components of RBAC should be harmless without significant food allergies. No serious, untoward side effects have been reported to the company by consumers nor observed during previous human studies. If any side effect does occur, the remedy is to discontinue until asymptomatic, and then reintroduce at 1/4 dosage, increasing by the same amount every 2 days, if uneventful, until full dosage is achieved. Dr. Ali will provide additional follow-up and consultation with any subject who experiences an untoward side effect.

A toxicology search for each component reveals no unique toxicity characteristic of the materials. As reported by Daiwa Health Development, the manufacturer of the product, thousands of people currently use RBAC (under the trade names BRM4 and PeakImmune 4), and Daiwa is unaware of significant toxicities. Daiwa applies the latest scientific methods to ensure the value and safety of their raw materials. Daiwa products are manufactured in state-of-the-art facilities, under strict quality control and environmental protection standards.

Participants will incur no additional appreciable psychological or social risks by participating in this study, although they may undergo psychological and physical discomfort sometimes. The process of interviewing during the assessment may cause discomfort. Discomfort or fatigue may also be experienced in completing the assessment battery.

Alternatives to this study for enhancing immune system functioning include prescription medications, exercise, dietary modification, and other nutritional supplements. The risks of medications can be very significant, including life-threatening, but the risk of taking nutritional supplements is not totally understood, since they are not regulated by the US Food and Drug Administration. Medications and nutritional supplements, as part of a change in lifestyle behaviors, may also prove to be beneficial for immune system functioning, but their long-term use has unknown consequences.

The information obtained in this study will help in determining the efficacy of using a rice bran extract nutritional supplement for enhancing immune system outcomes. By participating in the study, subjects may experience improved NK cell activity and cytokine functioning. The risk of participating in this study is reasonable because of the potential enhancements in immune system functioning with improved nutritional status.

Conditions
Family Member
Being tested
Rice Bran Arabinoxylan Compound (RBAC)
Keywords
NK cells cytotoxicity, dietary supplementation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Rice Bran Arabinoxylan Compound (RBAC)Dietary supplement

    Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.

Study groups in NCT02019628
Study groupRoleWhat they receive
BRM4 at a dosage level of 1 gram/dayExperimental60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day.
Receives: Dietary Supplement: Rice Bran Arabinoxylan Compound (RBAC)
BRM4 at a dosage level of 3 grams/dayExperimental60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day.
Receives: Dietary Supplement: Rice Bran Arabinoxylan Compound (RBAC)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Immune Functioning - NK Cell activity

    NK Cell activity at baseline, 48 hours, 1 week, 1 month, and 2 months.

    Measured: 60 days

  2. Immune Functioning - Cytokines

    Cytokines at baseline, 1 month, and 2 months.

    Measured: 60 days

Secondary outcomes (9)
  1. Bilirubin

    Bilirubin at baseline, 48 hours, 1 week, 1 month, and 2 months.

    Measured: 60 days

  2. Blood Pressure and Heart Rate

    Blood pressure and heart rate at baseline and 2 months.

    Measured: 60 days

  3. Physical Activity

    Physical activity will be assessed at baseline and 2-months follow-up by the Stanford 7-day Activity Recall. This instrument assesses the amount (number of hours) of moderate, physically challenging, and very physically challenging activities over the past 7 days. This instrument provides useful estimates of habitual physical activity for research, significantly agrees with daily self-report of physical activity, and has been validated for use in community settings.

    Measured: 60 days

  4. Functional Health and Well-being

    The SF-36v2™ Health Survey provides psychometrically-based physical and mental health summary measures and a preference-based health utility index. It is a generic measure that does not target a specific age, disease, or treatment group and will be assessed at baseline and 2-months follow-up.

    Measured: 60 days

  5. Creatinine

    Creatinine at baseline, 48 hours, 1 week, 1 month, and 2 months.

    Measured: 60 days

  6. Liver Function Tests

    Liver Function Tests at baseline, 48 hours, 1 week, 1 month, and 2 months.

    Measured: 60 days

  7. Body Mass Index

    Body weight and height to calculate body mass index (BMI) at baseline and 2 months.

    Measured: 60 days

  8. Percent Body Fat

    Skinfold caliper assessment to calculate percent body fat at baseline and 2 months.

    Measured: 60 days

  9. Waist to Hip Ratio

    Waist and hip circumference to calculate waist to hip ratio at baseline and 2 months.

    Measured: 60 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2013 (estimated)
  2. Study startNov 2009
  3. Primary completionApr 2011
  4. Study completionNov 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02019628
Sponsor's protocol ID
20090384
Status last verified
Oct 2023
First submitted
18 Dec 2013
Last updated
10 Oct 2023
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Rice Bran Arabinoxylan Compound (RBAC) in people with Family Member, run by University of Miami at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Immune Functioning - NK Cell activity (time frame: 60 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in